| Heading: |
Migraine: Drugs |
| Question ID: |
1809891 |
| UIN: |
57889 |
| House: |
Commons |
| Date tabled: |
2025-06-05 |
| Asking Member ID: |
5240 |
| Asking Member display name: |
Melanie Ward
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Melanie Ward
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of a supply shortage of Aimovig on people who experience migraines. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-12 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department is aware of a recent short term supply issue with one strength of Aimovig. We worked with NHS England, the Medicines and Healthcare products Regulatory Agency, and the devolved administrations to expedite resupply and have confirmed that st... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |